

Michigan Pharmacy and Therapeutics Committee
Meeting of December 4, 2007
DRAFT DRAFT DRAFT Minutes DRAFT DRAFT DRAFT

Members present: Drs. Nedd, Dillon, Dorfman, Fiechtner, Inman, Perri
Members absent: Drs. Arend, Bradley, Dake, Rogers, Van Loo
DUR Board members present: Karen Jonas, RPh
Staff present: Debera Eggleston, MD, Sue Moran, RN, Jacqueline Coleman, Tom Welch,
Sean Bodell, Annette Paul, RPh

Dr. Nedd changed the order of the Agenda, awaiting presence of a quorum of members, and started with **Public Comment**:

S. Moody, Pharm D, AstraZeneca, discussed Crestor and Atacand

J. Cwengros, Pharm D, Pfizer, discussed Lipitor

D. Fuhs, Pharm D, GSK, discussed Coreg CR

Dr. D. Tukul discussed a new product Azasite

T. Golden, Pharm D, Novartis, discussed a new product, Exforge, a fixed dose combination of amlodipine and valsartan

Later into the meeting M. Liepman, MD spoke to the Committee on Opioid dependence and its treatment with Suboxone, emphasizing the economic and health care system consequences of persons with untreated addictions, the success of using Suboxone for treating opioid dependence, and the barriers he sees to its use by the current system of prior authorization. Dr. Liepman would like to see Suboxone available without prior authorization for a year of treatment with the dose to be determined by the prescribing physician

The Minutes of the September 11, 2007 meeting were approved.

New Drugs

Following presentation of the drug products by Annette Paul and Giovannino Perri, the Committee recommended to the Department:

Exelon transdermal: add to the Michigan Pharmaceutical Product List (MPPL) and the Preferred Drug List (PDL) without prior authorization

Neupro: add to the MPPL and to the PDL with prior authorization

Divigel: add to the MPPL with prior authorization, as the active ingredient is available generically and has a MAC price

Altabax: add to the MPPL without prior authorization

Veramyst: add to the MPPL and PDL with prior authorization

Reclast: physician administered injectable

Supprelin LA: physician administered implant

Vyvanse: add to the MPPL and PDL with prior authorization

Azasite: add to the MPPL and create a separate PDL class in Ophthalmics without prior authorization

Line Extensions;

Following review, the Committee recommended to the Department:

Calomist: add to the MPPL with prior authorization

Zytopic: add to the MPPL with prior authorization

Review of PDL Classes

Following review of the Workgroup Recommendations and discussion, the Committee recommended to the Department the following:

Analgesics:**Narcotics-Long Acting**

No change to the current classification of drugs

Narcotics-Short and Intermediate acting

No change to the current classification of drugs

Non-Steroidal Anti-Inflammatory-COX II Inhibitors

Add chronic aspirin use as a point of sale electronic edit to the current edit recognizing anticoagulants and drugs such as methotrexate when authorizing Celebrex prescriptions

CNS Drugs:**Alzheimer's Dementia**

No change to the current classification of drugs in this class

Anti-Anxiety-General

Remove doxepin from this list

No other changes to the classification of drugs in this category

Drugs for ADHD

Maintain the clinical edit on drugs in this category

No change to the current classification of drugs in the class

Sedative Hypnotic Non Barbiturates

Remove chloral hydrate, chloral hydrate syrup, diphenhydramine, flurazepam from the class listing on the PDL

No other changes to the current classification of drugs in the class

The Committee reviewed the current clinical edit wherein use of one or more of these products for more than three months in the same beneficiary requires prior authorization for continued use. This protocol was again approved by the Committee.

Scheduling of 2008 Meetings:

The meetings will follow the same quarterly format

Tuesday, March 4, June 3, September 9, December 2 2008